Medical Pharmacology: Chapter: 25 — Pulmonary Pharmacology -- Module: 2 — Inhaled Corticosteroids and Combination Controller Therapy

Chapter: 25 — Pulmonary Pharmacology — Module: 2 — Inhaled Corticosteroids and Combination Controller Therapy
Tier: T3 (Clinical Vignette)

1. A 38-year-old woman with severe persistent asthma is maintained on high-dose fluticasone propionate 500 mcg/salmeterol 50 mcg twice daily via DPI (dry powder inhaler). Six weeks ago she developed refractory oropharyngeal candidiasis and was started on oral itraconazole 200 mg twice daily by her primary care physician. She now presents with four weeks of progressive facial rounding, central weight gain, easy bruising, proximal muscle weakness, and new-onset hypertension. Her 8 AM serum cortisol is 28 nmol/L (reference range 171–536 nmol/L). She denies starting any new oral corticosteroids. Which of the following best identifies the mechanism responsible for her presentation and the most appropriate immediate management?

A) She has developed primary adrenal insufficiency caused by direct itraconazole inhibition of adrenal CYP11B1 (steroid 11-beta-hydroxylase), reducing endogenous cortisol synthesis; the appropriate management is to stop itraconazole and begin physiologic hydrocortisone replacement at 15–20 mg per day in divided doses while continuing her current ICS regimen unchanged
B) She has developed autoimmune adrenal insufficiency (Addison disease) unrelated to her medications; itraconazole is a known trigger of antiadrenal antibody formation in susceptible individuals; the appropriate management is to stop itraconazole, measure anti-21-hydroxylase antibodies, and begin mineralocorticoid replacement with fludrocortisone in addition to hydrocortisone
C) Itraconazole is a potent CYP3A4 (cytochrome P450 3A4) inhibitor that has markedly impaired hepatic first-pass metabolism and systemic clearance of fluticasone propionate, producing iatrogenic glucocorticoid excess (Cushing's syndrome) with secondary HPA (hypothalamic-pituitary-adrenal) axis suppression; the appropriate immediate management is to discontinue itraconazole, switch to a non-azole antifungal or lower-interaction alternative, assess adrenal function with a stimulation test, and consider gradual ICS dose reduction once adrenal recovery is confirmed
D) She has developed secondary adrenal insufficiency caused by salmeterol-mediated suppression of ACTH (adrenocorticotropic hormone) release through beta-2 adrenergic receptor activation in pituitary corticotroph cells; the appropriate management is to stop salmeterol and switch to a SABA-only rescue regimen while continuing the ICS component and adding short-term hydrocortisone bridge therapy
E) She has developed glucocorticoid-induced Cushing's syndrome from cumulative systemic absorption of inhaled fluticasone propionate alone, without any contribution from itraconazole; the onset timing of six weeks after ICS initiation is consistent with this explanation; the appropriate management is to halve the ICS dose and monitor cortisol levels monthly until they normalize

ANSWER: C

Rationale:

This patient presents with classic iatrogenic Cushing's syndrome — facial rounding, central adiposity, easy bruising, proximal myopathy, hypertension — combined with a suppressed 8 AM cortisol confirming HPA axis suppression, and the timeline directly implicates the addition of itraconazole six weeks prior. Fluticasone propionate is metabolized extensively by hepatic CYP3A4, which produces near-complete first-pass extraction of the swallowed fraction and ongoing systemic clearance of pulmonary-absorbed drug. Itraconazole is one of the most potent CYP3A4 inhibitors in clinical use; co-administration can raise systemic fluticasone propionate concentrations 5- to 20-fold above expected levels, delivering glucocorticoid receptor occupancy equivalent to substantial systemic corticosteroid administration. The resulting glucocorticoid excess produces Cushing's syndrome, and sustained pituitary ACTH suppression explains her undetectable morning cortisol. Immediate management requires: discontinuation of itraconazole; switch to a non-azole or minimal-CYP3A4-interaction antifungal (such as nystatin or terbinafine depending on infection type); formal adrenal axis assessment with a short Synacthen (cosyntropin) stimulation test; and gradual, supervised ICS dose reduction once the interaction is resolved, since abrupt ICS withdrawal risks adrenal crisis in a patient with documented HPA suppression.

Option A: Option A is incorrect because itraconazole does have some inhibitory activity on mammalian CYP11B1, but primary adrenal insufficiency with a Cushingoid phenotype is contradictory — true primary adrenal insufficiency produces cortisol deficiency and skin hyperpigmentation, not glucocorticoid excess features such as facial rounding and central obesity; the clinical picture here is glucocorticoid excess, not deficiency.
Option B: Option B is incorrect because itraconazole does not trigger autoimmune adrenal insufficiency, and the clinical presentation is Cushingoid (excess), not Addisonian (deficiency); autoimmune primary adrenal insufficiency would produce cortisol deficiency with hyperpigmentation, not the adipogenic and catabolic features of glucocorticoid excess.
Option D: Option D is incorrect because salmeterol does not suppress ACTH release through pituitary beta-2 adrenergic receptor activation; this is not an established pharmacological mechanism, and HPA suppression from LABAs has not been documented; the Cushingoid phenotype and suppressed cortisol are not explained by salmeterol.
Option E: Option E is incorrect because fluticasone propionate at high inhaled doses can produce subtle HPA effects in some patients, but iatrogenic Cushing's syndrome developing six weeks after adding itraconazole — with perfectly timed chronology — is attributable to the drug interaction, not to cumulative ICS effect developing at a dose the patient had been tolerating before itraconazole was added.

2. A 64-year-old man with COPD (chronic obstructive pulmonary disease) and a post-bronchodilator FEV1 (forced expiratory volume in 1 second) of 48% predicted is currently on umeclidinium/vilanterol (LABA/LAMA dual bronchodilator therapy). He has had two moderate exacerbations treated with oral prednisone and antibiotics in the past 12 months. His blood eosinophil count measured at his last well visit (not during exacerbation) was 340 cells per microliter. He has never smoked in the past three years and has no prior history of pneumonia. He asks whether there is anything more that can be done to prevent future exacerbations. Which of the following represents the most appropriate next pharmacological step for this patient?

A) Add roflumilast (a PDE4 inhibitor) to his existing LABA/LAMA regimen because roflumilast is the preferred add-on therapy for all COPD patients with two or more exacerbations per year on dual bronchodilator therapy, and blood eosinophil count is not relevant when the primary goal is exacerbation prevention rather than airway inflammation phenotyping
B) Initiate azithromycin 250 mg three times weekly as prophylactic antibiotic therapy because recurrent moderate COPD exacerbations in a former smoker with moderate-to-severe airflow obstruction are driven by bacterial colonization rather than eosinophilic inflammation, and macrolide prophylaxis reduces exacerbation frequency more reliably than ICS in patients with eosinophil counts below 400 cells per microliter
C) No additional pharmacological therapy is indicated because two moderate exacerbations per year on dual bronchodilator therapy does not meet the threshold for escalation to triple therapy; GOLD guidelines require at least one hospitalization for COPD exacerbation or three moderate exacerbations per year before ICS addition is considered
D) Switch from umeclidinium/vilanterol to a single-inhaler triple therapy product containing fluticasone furoate/umeclidinium/vilanterol but only if his eosinophil count can be confirmed above 300 cells per microliter on two separate measurements taken at least 90 days apart, because single-measurement eosinophil counts are not sufficiently reproducible to guide ICS initiation decisions in COPD
E) Add ICS to his existing LABA/LAMA regimen by escalating to single-inhaler triple therapy (such as fluticasone furoate/umeclidinium/vilanterol), because his eosinophil count of 340 cells per microliter is above the 300 cells per microliter threshold predicting strong ICS exacerbation-reduction benefit, and two moderate exacerbations in 12 months on dual bronchodilator therapy is a recognized indication for ICS escalation in GOLD guidelines

ANSWER: E

Rationale:

This patient meets both criteria that GOLD guidelines identify as supporting ICS addition to LABA/LAMA dual bronchodilator therapy: a blood eosinophil count above the 300 cells per microliter threshold predicting strong ICS exacerbation-reduction benefit, and two moderate exacerbations in the past year despite dual bronchodilator therapy. The IMPACT trial demonstrated that single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) reduced moderate and severe exacerbation rates by 25% relative to LABA/LAMA and by 15% relative to ICS/LABA in this patient population. His absence of prior pneumonia history and eosinophil count above 300 cells per microliter further support a favorable benefit-risk profile for ICS addition. Escalating to triple therapy is the correct next step.

Option A: Option A is incorrect because roflumilast is the preferred add-on for patients with COPD with a chronic bronchitis phenotype (productive cough for three months per year for two consecutive years) and recurrent exacerbations, and eosinophil count is directly relevant to the treatment choice; in a patient with an eosinophil count above 300 cells per microliter, ICS addition is the biomarker-supported choice rather than roflumilast.
Option B: Option B is incorrect because azithromycin prophylaxis is considered in patients with recurrent exacerbations who have failed or are not candidates for ICS-containing regimens; it is not the preferred initial escalation step in a patient whose biomarker profile strongly predicts ICS benefit, and eosinophil counts above 300 cells per microliter do not redirect therapy away from ICS toward macrolide prophylaxis.
Option C: Option C is incorrect because GOLD guidelines do not require hospitalization or three exacerbations before ICS consideration; two moderate exacerbations per year on dual bronchodilator therapy is an established indication for ICS escalation, particularly when eosinophil count supports predicted benefit.
Option D: Option D is incorrect because GOLD guidelines do not require two confirmed measurements 90 days apart before acting on an eosinophil count; while eosinophil counts can fluctuate — particularly during acute exacerbations or systemic corticosteroid use — a measurement of 340 cells per microliter at a well visit (not during exacerbation) is a valid basis for ICS escalation decisions without requiring serial confirmation in stable outpatients.

3. A 10-year-old girl with moderate persistent asthma has been on medium-dose budesonide 200 mcg twice daily for two years with good asthma control. At her annual visit, her pediatrician notes that her height velocity has dropped from the 55th to the 18th percentile over the past 18 months. She uses a spacer consistently. Her asthma has been well-controlled throughout, with no exacerbations and SABA use less than twice per month. Her parents ask whether her ICS should be stopped. Which of the following best represents the appropriate management of her growth concern while maintaining asthma control?

A) Attempt to reduce budesonide to the lowest dose that maintains asthma control (a 25–50% dose reduction if she meets step-down criteria with three months of sustained control), continue annual height velocity monitoring, and consider switching to an ICS with lower systemic bioavailability such as beclomethasone dipropionate or ciclesonide if dose reduction alone does not restore growth velocity; complete ICS discontinuation is not appropriate given her moderate persistent asthma
B) Discontinue budesonide immediately and replace it with a leukotriene receptor antagonist (LTRA) monotherapy at the maximum approved pediatric dose, because LTRAs have no glucocorticoid receptor activity and produce no growth suppression; the growth velocity decline proves that the ICS benefit-risk ratio is now unfavorable and ICS should not be restarted unless she develops severe uncontrolled asthma requiring emergency department care
C) Continue the current budesonide dose unchanged because growth velocity decline on ICS is a well-documented but transient effect limited to the first year of ICS initiation; after 18 months of ICS use, growth velocity should have normalized regardless of the measured decline, and a height velocity at the 18th percentile simply represents regression to her genetic growth trajectory rather than ICS-induced suppression
D) Switch immediately from medium-dose budesonide to high-dose fluticasone propionate because fluticasone propionate has higher GR (glucocorticoid receptor) binding affinity than budesonide, allowing the same anti-inflammatory effect to be achieved at a lower microgram dose; the lower microgram dose of fluticasone propionate will reduce systemic glucocorticoid exposure compared with the current budesonide regimen and restore growth velocity
E) Add exogenous growth hormone (GH) therapy to her current regimen to counteract ICS-mediated suppression of the GH/IGF-1 axis (insulin-like growth factor 1 axis) while continuing budesonide at the current dose; exogenous GH administration is the standard-of-care intervention for ICS-induced growth suppression in children with moderate persistent asthma and is approved by the FDA for this indication

ANSWER: A

Rationale:

Growth velocity decline in a child on medium-dose ICS is an established adverse effect requiring attention but not panic discontinuation of asthma controller therapy. The appropriate management balances the real risk of ICS-induced growth suppression against the equally real risks of undertreated moderate persistent asthma — which itself impairs growth through chronic hypoxia, sleep disruption, systemic inflammation, and increased need for systemic corticosteroids during exacerbations. Since this patient has been well-controlled for at least three months (meeting step-down criteria), a 25–50% ICS dose reduction is both clinically appropriate and guideline-consistent, and represents the correct first intervention. This preserves asthma control while reducing the systemic glucocorticoid burden responsible for growth suppression. If dose reduction alone is insufficient, switching to an ICS agent with lower systemic bioavailability — such as beclomethasone dipropionate (with its prodrug activation profile and lower systemic absorption) or ciclesonide (the prodrug with low oropharyngeal and low systemic activation) — at an equivalent anti-inflammatory dose may further reduce systemic glucocorticoid exposure. Annual height velocity monitoring is a clinical standard for all children on ICS therapy and should continue. Abrupt discontinuation of ICS in moderate persistent asthma risks loss of control and oral corticosteroid exposure, which is far more growth-suppressive than inhaled therapy.

Option B: Option B is incorrect because LTRA monotherapy is substantially less effective than medium-dose ICS for moderate persistent asthma; abrupt complete ICS discontinuation risks asthma loss of control, exacerbations, and oral corticosteroid exposure that would be far more growth-suppressive; and LTRAs, while lacking glucocorticoid activity, are not equivalent controller agents for moderate persistent disease.
Option C: Option C is incorrect because ICS-induced growth velocity suppression is not limited to the first year; it can persist with continued ICS use at doses producing meaningful systemic exposure, and a documented decline from the 55th to 18th percentile over 18 months warrants clinical action rather than reassignment to genetic trajectory.
Option D: Option D is incorrect because switching to high-dose fluticasone propionate would increase, not decrease, systemic glucocorticoid exposure; fluticasone propionate has higher GR binding affinity than budesonide, but its systemic bioavailability from lung absorption is also significant, and prescribing high-dose fluticasone propionate to reduce ICS-related growth suppression is pharmacologically counterproductive.
Option E: Option E is incorrect because exogenous growth hormone therapy is not a standard-of-care or FDA-approved intervention for ICS-induced growth suppression in asthmatic children; the management of ICS-induced growth effects is through optimizing ICS dosing and agent selection, not by adding exogenous GH.

4. A 31-year-old woman at 14 weeks gestation presents to her obstetrician for a routine antenatal visit. She has moderate persistent asthma and has been well-controlled on fluticasone propionate 250 mcg twice daily via pMDI (pressurized metered-dose inhaler) with a spacer for the past 18 months. Her asthma has been stable with no exacerbations. She asks whether her inhaler is safe during pregnancy and whether she should stop it to protect her baby. Which of the following represents the most appropriate management of her ICS therapy?

A) Discontinue fluticasone propionate immediately and manage her asthma with as-needed SABA (short-acting beta-2 agonist) alone for the remainder of the pregnancy, because all ICS cross the placenta and expose the fetus to glucocorticoid receptor activation during organogenesis; the risk of fetal HPA (hypothalamic-pituitary-adrenal) axis programming from ICS outweighs the asthma control benefit in a patient whose disease is currently well-controlled
B) Continue fluticasone propionate at the current dose without modification because it has an oral bioavailability of less than 1%, ensuring that essentially no active drug reaches the placenta through the gastrointestinal route; the low oral bioavailability makes it the safest ICS option in pregnancy, superior to budesonide which has higher systemic absorption from the lung
C) Reduce fluticasone propionate to the lowest licensed dose (100 mcg twice daily) and add montelukast as an LTRA (leukotriene receptor antagonist) to compensate for the reduced ICS dose; this combination strategy minimizes fetal ICS exposure while maintaining asthma control through an ICS-sparing effect of the LTRA
D) Switch from fluticasone propionate to budesonide at an equivalent dose because budesonide is the ICS with the largest human pregnancy safety database — including Swedish Medical Birth Registry data from thousands of exposed pregnancies — and is specifically identified as the preferred ICS during pregnancy in GINA (Global Initiative for Asthma) guidelines; ICS must be continued because uncontrolled asthma poses significant risks to both mother and fetus including preeclampsia, preterm birth, and intrauterine growth restriction
E) Continue fluticasone propionate and add a daily oral folic acid supplement at a higher-than-standard dose (5 mg versus 0.4 mg) to offset any potential teratogenic effects of ICS on neural tube development, because glucocorticoids interfere with folate metabolism in the developing neural tube during the first trimester

ANSWER: D

Rationale:

The correct management integrates two principles that must be communicated to this patient. First, ICS therapy must be continued throughout pregnancy — uncontrolled asthma is more dangerous to the fetus than appropriately dosed ICS. Poorly controlled asthma during pregnancy is associated with preeclampsia, preterm labor, intrauterine growth restriction, low birth weight, and maternal hypoxia, all of which pose direct fetal risk. Stopping or reducing ICS in a well-controlled patient risks losing that control and precipitating outcomes more harmful than the ICS itself. Second, the specific ICS should be switched from fluticasone propionate to budesonide. GINA guidelines identify budesonide as the preferred ICS during pregnancy based on the largest human pregnancy safety database of any ICS agent — specifically the systematically analyzed Swedish Medical Birth Registry and related Scandinavian datasets covering thousands of budesonide-exposed pregnancies, which have not demonstrated statistically significant increases in congenital malformations, preterm birth, or low birth weight. Fluticasone propionate, while also used in pregnancy, has a smaller systematically analyzed pregnancy registry compared with budesonide. The switch to budesonide at an equivalent dose maintains asthma control while providing the most evidence-based ICS choice for the pregnant patient.

Option A: Option A is incorrect because stopping ICS in a patient with moderate persistent asthma poses direct fetal risk through loss of asthma control; the premise that all ICS fetal exposure is harmful is contradicted by the established safety data for budesonide; and SABA-only management is inadequate for moderate persistent asthma.
Option B: Option B is incorrect because low oral bioavailability does not guarantee placental safety — fluticasone propionate absorbed from the lung does reach the systemic circulation and crosses the placenta; furthermore, the guideline preference is based on human registry evidence, not on bioavailability calculations, and budesonide is specifically preferred over fluticasone propionate.
Option C: Option C is incorrect because reducing ICS below an effective dose risks asthma exacerbation; adding montelukast as an ICS-sparing strategy during pregnancy introduces a drug with a different evidence base without compelling safety advantage over maintaining effective-dose budesonide; the correct approach is to maintain effective controller therapy with the preferred pregnancy-safe agent.
Option E: Option E is incorrect because glucocorticoids do not interfere with folate metabolism in a manner requiring high-dose folic acid supplementation; high-dose folic acid at 5 mg is indicated for women with prior neural tube defect pregnancies or on antiepileptic drugs — not for ICS use — and this is not an appropriate or evidence-based intervention for ICS-exposed pregnancies.

5. A 72-year-old man with severe COPD (chronic obstructive pulmonary disease) has been on single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) for 20 months. His blood eosinophil count is 61 cells per microliter, measured at a routine well visit. He has had no COPD exacerbations since starting triple therapy, but has required two hospitalizations for community-acquired pneumonia in the past 14 months. His pulmonologist is reviewing his regimen at his quarterly visit. He has moderate nutritional deficiency (BMI 19.2 kg/m²) and severe airflow obstruction (FEV1 34% predicted). Which of the following most accurately reflects the appropriate management of his ICS therapy at this visit?

A) Continue triple therapy unchanged because his exacerbation-free course proves the regimen is effective; pneumonia is an expected complication of COPD itself and is not attributable to ICS in a patient on standard-dose fluticasone furoate; changing a regimen that is preventing exacerbations would expose him to high exacerbation risk
B) Withdraw the ICS component while continuing LABA/LAMA dual bronchodilator therapy, because this patient fulfills all three GOLD criteria supporting ICS withdrawal: eosinophil count below 100 cells per microliter predicting minimal ICS exacerbation-reduction benefit, absence of COPD exacerbations suggesting that dual bronchodilation rather than ICS is driving his exacerbation control, and two ICS-attributable pneumonia hospitalizations representing recurring serious harm; his low BMI and severe airflow obstruction further elevate his pneumonia risk
C) Reduce the fluticasone furoate dose by 50% while maintaining the LAMA and LABA components at their current doses, stepping from high-dose to medium-dose ICS within the triple therapy combination; this graduated dose reduction minimizes exacerbation risk while progressively reducing pneumonia exposure, and is preferred over abrupt ICS discontinuation in patients who have been on triple therapy for more than 12 months
D) Add prophylactic azithromycin 250 mg three times weekly to his current triple therapy regimen to reduce the risk of pneumococcal pneumonia while maintaining full-dose ICS; macrolide prophylaxis is the preferred strategy for managing ICS-associated pneumonia risk in COPD patients on triple therapy who have blood eosinophil counts below 100 cells per microliter
E) Temporarily suspend triple therapy for 30 days and reassess his eosinophil count off ICS before making a permanent decision, because fluticasone furoate suppresses peripheral blood eosinophil counts and his true eosinophil count may be higher than 61 cells per microliter when measured without systemic corticosteroid influence; if the off-treatment count exceeds 100 cells per microliter, triple therapy should be resumed

ANSWER: B

Rationale:

This patient presents a textbook convergence of all three GOLD guideline criteria supporting ICS withdrawal in COPD. First, his blood eosinophil count of 61 cells per microliter is well below the 100 cells per microliter threshold below which ICS-derived exacerbation prevention benefit is unlikely; patients in this biomarker stratum are predicted not to benefit from ICS-containing regimens while remaining at elevated ICS-associated pneumonia risk. Second, his 20 months without COPD exacerbations on triple therapy strongly suggests that his dual bronchodilator backbone — umeclidinium as LAMA and vilanterol as LABA — is providing his exacerbation control, since ICS benefit is pharmacologically unlikely at his eosinophil level. Third, two hospitalizations for community-acquired pneumonia in 14 months represent serious, recurring ICS-attributable harm; his additional patient-specific risk factors — low BMI of 19.2 kg/m² and severe airflow obstruction (FEV1 34% predicted) — further elevate his pneumonia risk. Together these factors produce a benefit-risk calculation that decisively favors ICS withdrawal. Continuing LABA/LAMA dual bronchodilator therapy maintains the bronchodilator protection responsible for his exacerbation-free course.

Option A: Option A is incorrect because attributing his exacerbation-free course to the ICS component ignores his eosinophil count; at below 100 cells per microliter, ICS-mediated exacerbation prevention is pharmacologically unlikely, and the exacerbations are more plausibly controlled by dual bronchodilation; the pneumonia hospitalizations are serious harm that cannot be dismissed as expected COPD complications when ICS is a known causal factor in patients with his risk profile.
Option C: Option C is incorrect because reducing ICS dose within triple therapy is not the guideline-endorsed approach to ICS-associated pneumonia in a patient with all three withdrawal criteria; the correct intervention is ICS withdrawal, not dose titration, and there is no evidence that half-dose ICS maintains exacerbation prevention while meaningfully reducing pneumonia risk in a patient predicted not to benefit from ICS at any dose.
Option D: Option D is incorrect because adding azithromycin prophylaxis to an ICS-containing regimen does not address the fundamental problem — that ICS is producing harm without commensurate benefit in this patient; the correct first step is ICS withdrawal, and azithromycin might subsequently be considered for exacerbation prevention if he develops recurrent exacerbations after ICS withdrawal.
Option E: Option E is incorrect because fluticasone furoate as an inhaled rather than systemic corticosteroid does not produce the degree of peripheral blood eosinophil suppression that would invalidate a clinical blood count; suspending triple therapy for 30 days to reassess eosinophil count is not a guideline-endorsed protocol before ICS withdrawal, and a count of 61 cells per microliter at a routine well visit is a valid basis for the withdrawal decision.

6. A 22-year-old male recreational soccer player has mild-to-moderate persistent asthma currently managed on low-dose fluticasone propionate 100 mcg twice daily (GINA step 2). He reports good control at rest but has breakthrough wheeze and chest tightness during and after exercise three to four times per week, requiring SABA (short-acting beta-2 agonist) rescue during each episode. His spirometry shows FEV1 (forced expiratory volume in 1 second) 74% predicted with a post-salbutamol improvement of 28%. His asthma control questionnaire score is 16 (indicating not well-controlled). He has had no exacerbations requiring oral corticosteroids. His inhaler technique is correct and adherence is confirmed. His physician plans GINA step 3 escalation. Which of the following step 3 treatment options is best matched to this patient's clinical phenotype?

A) Increase to medium-dose fluticasone propionate monotherapy (400 mcg twice daily), because his exercise-triggered symptoms and high SABA use indicate ongoing airway inflammation between exercise bouts that requires greater ICS anti-inflammatory intensity; LABA addition is premature before maximizing ICS dose in a patient whose exacerbation burden is low
B) Switch to as-needed budesonide/formoterol SMART (Single Maintenance And Reliever Therapy) strategy as the sole controller and rescue regimen, because SMART is the preferred GINA step 3 option for exercise-triggered asthma in young athletic patients; salmeterol-based combinations are inappropriate for this patient because they cannot be used for rescue
C) Add a LABA as a fixed-dose low-dose ICS/LABA combination (such as fluticasone propionate/salmeterol or budesonide/formoterol), because his high post-bronchodilator reversibility of 28% and exercise-triggered phenotype indicate a predominantly bronchospastic mechanism where sustained beta-2 adrenergic receptor-mediated bronchodilation throughout his activity period will provide greater symptom control than increasing the ICS dose alone
D) Add montelukast (an LTRA, leukotriene receptor antagonist) to his current low-dose ICS rather than adding a LABA, because exercise-induced bronchoconstriction is driven specifically by leukotriene release from mast cells activated by post-exercise airway cooling and desiccation; montelukast is more targeted than LABA for this specific mechanism and is GINA's preferred step 3 add-on for exercise-triggered asthma
E) Initiate low-dose oral prednisolone at 5 mg daily for four weeks to achieve rapid asthma control, then step down to the current low-dose ICS; short oral corticosteroid induction is the preferred GINA step 3 approach for young patients with high reversibility and exercise-triggered symptoms because it rapidly reduces airway hyperresponsiveness that ICS dose increases or LABA addition cannot address on the required timescale

ANSWER: C

Rationale:

This patient's clinical phenotype strongly favors LABA addition as the step 3 escalation choice. His post-bronchodilator reversibility of 28% — substantially above the 12% threshold for significant reversibility — demonstrates that beta-2 adrenergic receptor-mediated smooth muscle relaxation produces meaningful symptom relief in his airways; this pharmacological responsiveness predicts that a LABA sustaining bronchodilation throughout his exercise periods will directly address his predominant symptom driver. His exclusively exercise-triggered pattern and excellent baseline control at rest are consistent with a predominantly bronchospastic rather than pervasively inflammatory phenotype. Fixed-dose low-dose ICS/LABA combination (such as fluticasone propionate/salmeterol or budesonide/formoterol twice daily) provides both the anti-inflammatory ICS component and sustained beta-2 receptor activation covering his exercise windows, making it pharmacologically well-matched to his situation. All three GINA step 3 options are equally endorsed and individualized, and for this patient the clinical reasoning favors ICS/LABA over ICS dose doubling.

Option A: Option A is incorrect because increasing ICS to medium-dose monotherapy is less well-matched to a patient whose primary unmet need is bronchospasm during exercise rather than pervasive inflammation; high post-bronchodilator reversibility is the specific phenotypic signal that favors LABA addition over ICS dose escalation at step 3.
Option B: Option B is incorrect because SMART with budesonide/formoterol is a valid step 3 option, but characterizing it as "preferred" for exercise-triggered asthma in athletes is overstated; SMART's evidence base in mild asthma (SYGMA, Novel START) supports its use for exacerbation-prone patients, and the as-needed-only rescue design may not provide optimal sustained bronchodilator coverage for predictable exercise-triggered symptoms; ICS/LABA fixed-dose combination with consistent dosing is also well-suited for this patient.
Option D: Option D is incorrect because while leukotriene receptor antagonists do reduce exercise-induced bronchoconstriction (through cysteinyl leukotriene inhibition), LTRA addition is not GINA's preferred step 3 option for this patient and is not superior to LABA addition in patients with high bronchodilator reversibility; LTRA monotherapy or add-on is less effective than ICS/LABA in most patients with persistent asthma.
Option E: Option E is incorrect because short-course oral corticosteroids are used for acute exacerbation rescue, not as an induction strategy to enable step 3 escalation in stable but uncontrolled asthma; initiating oral prednisolone in a patient with no severe exacerbation is a disproportionate and guideline-inconsistent approach to step-up management.

7. A 48-year-old professional opera singer with severe persistent asthma has been on high-dose fluticasone propionate/salmeterol 500/50 mcg twice daily for three years. She presents with eight months of progressive hoarseness that has significantly impaired her professional singing. She reports consistent spacer use with every pMDI (pressurized metered-dose inhaler) inhalation and post-inhalation mouth rinsing. Laryngoscopy performed by an otolaryngologist reveals normal vocal cord mucosa without erythema, plaques, or exudate; there is incomplete glottic closure and altered vocal cord tension on phonation with normal mucosal wave. A course of oral fluconazole two months ago produced no improvement. Which of the following best identifies the mechanism and appropriate management?

A) She has candidal laryngitis refractory to fluconazole therapy, most likely caused by a non-albicans Candida species resistant to azole antifungals; the appropriate management is to obtain a laryngeal swab for culture and sensitivity and prescribe amphotericin B lozenges while continuing her current ICS regimen and spacer technique
B) She has salmeterol-induced vocal cord dysfunction caused by beta-2 adrenergic receptor activation in the thyroarytenoid muscle, producing sustained relaxation and incomplete glottic closure; switching to a LABA-free regimen (high-dose ICS monotherapy) while adding a short-acting anticholinergic inhaler for rescue bronchospasm will resolve the vocal cord dysfunction
C) She has functional dysphonia caused by the psychological stress of severe persistent asthma and should be referred to a speech-language pathologist for voice therapy; her laryngoscopic findings of incomplete glottic closure with normal mucosa are consistent with muscle tension dysphonia unrelated to any pharmacological mechanism of her ICS regimen
D) She has ICS-induced laryngeal candidiasis that has penetrated to the deep laryngeal submucosal tissue, below the visible mucosal surface; the absence of visible plaques on laryngoscopy reflects submucosal invasion rather than absence of infection, and she requires intravenous voriconazole for systemic antifungal penetration to the submucosa
E) She has ICS-induced laryngeal myopathy — glucocorticoid receptor-mediated steroid myopathy of the intrinsic laryngeal muscles producing functional vocal cord paresis — which is distinct from candidal laryngitis, is not prevented by spacer use or mouth rinsing, and was correctly unresponsive to fluconazole; appropriate management includes switching to ciclesonide (a prodrug with lower laryngeal tissue glucocorticoid receptor activity) or reducing ICS dose to the lowest that maintains asthma control, with referral to a laryngologist experienced with professional voice users

ANSWER: E

Rationale:

This patient's clinical presentation is the prototypical picture of ICS-induced laryngeal myopathy rather than candidal laryngitis, distinguished by several specific features. Normal vocal cord mucosa on laryngoscopy — no erythema, plaques, or exudate — excludes active candidal laryngitis as the current cause. The laryngoscopic finding of incomplete glottic closure with altered vocal cord tension and normal mucosal wave reflects myopathic dysfunction of the intrinsic laryngeal muscles rather than mucosal pathology. Her correct consistent spacer use and mouth rinsing exclude inadequate technique as a contributing factor, and the absence of response to two months of oral fluconazole definitively eliminates candidal infection as the etiology. ICS-induced laryngeal myopathy results from sustained glucocorticoid receptor activation in laryngeal muscle tissue — particularly the thyroarytenoid, lateral cricoarytenoid, and posterior cricoarytenoid muscles — producing local steroid myopathy that impairs the fine muscle tension control required for professional vocal performance. This mechanism is not prevented by spacer use because laryngeal muscle tissue receives glucocorticoid exposure both from direct deposition and from systemically absorbed drug; reducing the active glucocorticoid concentration at laryngeal tissue is the appropriate mechanistic target. Switching to ciclesonide (a prodrug with low laryngeal tissue activation because oropharyngeal esterase activity is insufficient to convert it to des-ciclesonide) or reducing the ICS dose to the minimum effective level are the pharmacologically appropriate interventions. Referral to a laryngologist with experience in professional voice is appropriate given the occupational stakes.

Option A: Option A is incorrect because the laryngoscopic appearance definitively excludes active candidal infection — whether azole-susceptible or resistant; non-albicans Candida resistance is not the explanation for a normal-appearing mucosa, and amphotericin B lozenges are not the appropriate next step when laryngoscopy shows no infection.
Option B: Option B is incorrect because salmeterol does not cause vocal cord dysfunction through beta-2 receptor activation in laryngeal striated muscle; beta-2 agonists relax airway smooth muscle but do not produce relaxation of the skeletal muscle fibers in the intrinsic laryngeal muscles; the mechanism of laryngeal dysfunction here is steroid myopathy, not LABA-mediated relaxation.
Option C: Option C is incorrect because muscle tension dysphonia is a functional disorder associated with excess laryngeal muscle tension, not incomplete glottic closure and reduced vocal cord tension; and attributing the findings to psychological stress ignores the specific pharmacological mechanism that explains them; speech therapy alone without addressing the ICS myopathy would be inadequate management.
Option D: Option D is incorrect because ICS-induced candidal infection does not produce submucosal invasion in immunocompetent patients; laryngeal candidiasis produces visible surface mucosal plaques and erythema, not submucosal disease requiring intravenous antifungals; the normal mucosal appearance on laryngoscopy excludes rather than confirms deep tissue infection.

8. A pulmonologist is reviewing four patients with asthma who have been referred after their primary care physicians asked whether they are candidates for SMART (Single Maintenance And Reliever Therapy) strategy. Patient 1 is a 25-year-old woman with mild persistent asthma currently on low-dose budesonide monotherapy who has had two moderate exacerbations in 18 months. Patient 2 is a 34-year-old man with moderate persistent asthma currently on fluticasone propionate/salmeterol 250/50 mcg twice daily who reports good control but wishes to simplify his regimen by using one inhaler for both maintenance and rescue. Patient 3 is a 19-year-old woman with mild asthma currently on low-dose ICS who has good baseline control with occasional SABA use for exercise triggers. Patient 4 is a 41-year-old man with moderate persistent asthma currently on low-dose budesonide who is uncontrolled, using his salbutamol inhaler daily, and who asks whether switching to SMART could improve his management. Which patient is the least appropriate candidate for SMART strategy?

A) Patient 2, because SMART requires a formoterol-containing ICS/LABA combination to serve as both maintenance and rescue; salmeterol's slow onset of approximately 10 to 20 minutes makes fluticasone propionate/salmeterol pharmacologically unsuitable for rescue use, and SMART cannot be implemented by simply designating any ICS/LABA combination as the rescue inhaler
B) Patient 1, because SMART is contraindicated in patients who have had two or more moderate exacerbations in the prior 18 months; GINA guidelines restrict SMART to patients with a history of no more than one exacerbation per year, and Patient 1's exacerbation frequency places her in a severity category where only fixed-dose twice-daily combination therapy is endorsed
C) Patient 3, because SMART is not appropriate for patients with exercise-triggered asthma; the as-needed dosing pattern of SMART does not provide sufficient bronchodilator coverage during the exercise period itself, and patients with predominantly exercise-triggered symptoms should use fixed-dose twice-daily ICS/LABA with pre-exercise SABA rather than as-needed budesonide/formoterol
D) Patient 4, because SMART is contraindicated in patients who are currently using daily SABA rescue; GINA guidelines require that SABA use be reduced to less than twice weekly before SMART initiation, since daily SABA use indicates a degree of airway instability that makes the as-needed ICS/LABA dosing pattern unreliable for maintaining control
E) Patient 3, because SMART can only be prescribed to patients currently using medium-dose or higher ICS monotherapy; patients on low-dose ICS are ineligible for SMART because the budesonide dose delivered per rescue inhalation in SMART is insufficient to achieve any anti-inflammatory effect in airways that have not already been primed by medium-dose scheduled ICS therapy

ANSWER: A

Rationale:

The critical pharmacological requirement for SMART is that the ICS/LABA combination used for both maintenance and rescue must contain a LABA with rapid enough onset to serve as effective rescue bronchodilation. Formoterol meets this requirement — it achieves near-maximal bronchodilation within 1 to 3 minutes, comparable to SABA agents. Salmeterol does not meet this requirement — it achieves peak bronchodilation only after 10 to 20 minutes due to its exosite binding mechanism, which is too slow for effective rescue of acute breakthrough symptoms. Patient 2 is currently on fluticasone propionate/salmeterol and wishes to implement SMART by using this inhaler as rescue; this is pharmacologically inappropriate because salmeterol's slow onset means that relief of acute bronchospasm will be delayed by 10 to 20 minutes, which is clinically unacceptable for rescue use and potentially dangerous. SMART is only pharmacologically viable with budesonide/formoterol; no salmeterol-containing product can be used in a SMART strategy regardless of the ICS partner. The other three patients — Patient 1 (exacerbation-prone mild asthma), Patient 3 (exercise-triggered mild asthma), and Patient 4 (uncontrolled on low-dose ICS) — all have clinical profiles for which budesonide/formoterol SMART is a GINA-endorsed option or at least a reasonable consideration.

Option B: Option B is incorrect because GINA guidelines do not restrict SMART to patients with no more than one exacerbation per year; the SYGMA trials specifically enrolled patients with mild asthma including those with prior exacerbations, and exacerbation prevention is one of the key arguments in favor of as-needed budesonide/formoterol in mild persistent asthma.
Option C: Option C is incorrect because exercise-triggered asthma is not a contraindication to SMART; as-needed budesonide/formoterol taken before exercise can serve as pre-exercise bronchodilator prophylaxis as well as rescue therapy, and GINA does not exclude exercise-triggered patients from SMART eligibility.
Option D: Option D is incorrect because daily SABA use is not a formal contraindication to SMART; in fact, patients using SABA frequently — indicating uncontrolled asthma — may benefit from switching to as-needed budesonide/formoterol to improve exacerbation prevention; GINA guidelines note that high SABA use is one of the triggers for reassessing controller therapy, which can include SMART initiation.
Option E: Option E is incorrect because there is no guideline requirement for prior medium-dose ICS priming before SMART initiation; SMART has been studied and endorsed in patients previously on low-dose ICS monotherapy, and the budesonide dose in each rescue inhalation does not require prior airway priming by scheduled medium-dose therapy to be effective.

9. A 69-year-old man with moderate COPD (chronic obstructive pulmonary disease) presents to the emergency department with three days of productive cough, fever, and worsening dyspnea. Chest radiography confirms right lower lobe consolidation. He has been on fluticasone propionate/salmeterol 500/50 mcg twice daily for four years. His blood eosinophil count from his last outpatient visit three months ago was 78 cells per microliter. He has had no COPD exacerbations in the past two years but this is his second hospitalization for pneumonia in 18 months. Which of the following best describes the appropriate management of both his acute illness and his longer-term ICS regimen?

A) Treat the pneumonia with antibiotics and continue fluticasone propionate/salmeterol unchanged, because COPD patients on ICS have higher rates of respiratory infection generally and the pneumonia does not constitute a specific pharmacological signal; changing a regimen that has prevented COPD exacerbations for four years would expose him to unacceptable exacerbation risk during his recovery
B) Treat the pneumonia with antibiotics, then permanently discontinue all inhaled therapy including salmeterol once he recovers, because COPD complicated by recurrent pneumonia indicates that inhaled drug delivery to the airways is producing local immunosuppression at a severity that makes continued bronchodilator therapy unsafe in this patient
C) Treat the pneumonia with antibiotics and add prophylactic fluconazole to prevent secondary fungal superinfection driven by ICS-induced local immunosuppression, then continue the current ICS/LABA regimen unchanged after recovery; azole antifungals are safe to combine with fluticasone propionate because they reduce oropharyngeal Candida burden without meaningfully affecting fluticasone pharmacokinetics
D) Treat the pneumonia with appropriate antibiotics; after recovery, reassess his ICS regimen in light of his eosinophil count of 78 cells per microliter — below the 100 cells per microliter threshold predicting minimal ICS exacerbation-reduction benefit — and his second ICS-attributable pneumonia hospitalization; given these findings, withdrawing the ICS while continuing salmeterol (and considering LAMA addition for dual bronchodilator coverage) is appropriate, with roflumilast or azithromycin as alternatives for exacerbation prevention if needed
E) Treat the pneumonia with antibiotics, then switch from fluticasone propionate/salmeterol to budesonide/formoterol at an equivalent anti-inflammatory dose, because budesonide-containing combinations carry the same magnitude of pneumonia risk as fluticasone propionate-containing combinations in COPD; changing the ICS agent does not reduce pneumonia risk and the switch provides no clinically meaningful safety benefit

ANSWER: D

Rationale:

This patient's clinical picture requires two sequential management decisions: acute and long-term. Acutely, community-acquired pneumonia is treated with appropriate antibiotics based on severity assessment and local resistance patterns, with his ICS continued during acute illness (since acute ICS discontinuation during respiratory exacerbation does not benefit the patient). The longer-term ICS reassessment is clinically urgent given the convergence of two factors: his eosinophil count of 78 cells per microliter — well below the 100 cells per microliter GOLD threshold below which ICS exacerbation-reduction benefit is unlikely and pneumonia risk is elevated — and his second pneumonia hospitalization in 18 months, representing recurring ICS-attributable serious harm. At this eosinophil level and with his two-year exacerbation-free course suggesting that his LABA is providing his exacerbation control, the benefit-risk analysis for continued ICS is unfavorable. Withdrawing the ICS while maintaining salmeterol and adding umeclidinium or tiotropium as LAMA for dual bronchodilator coverage provides evidence-based bronchodilator protection without continued ICS-associated pneumonia risk. Roflumilast (if he has chronic bronchitis phenotype) or azithromycin prophylaxis are alternative options for exacerbation prevention without ICS if he subsequently develops recurrent exacerbations on LABA/LAMA.

Option A: Option A is incorrect because attributing the exacerbation-free course to fluticasone propionate is not pharmacologically supported at his eosinophil level; the ICS component is unlikely to be contributing meaningful exacerbation prevention, the LABA is more plausibly responsible, and two pneumonia hospitalizations represent concrete harm that cannot be dismissed as a non-specific background infection rate.
Option B: Option B is incorrect because discontinuing all inhaled therapy including salmeterol is pharmacologically unjustified; salmeterol does not cause pneumonia and is providing bronchodilator benefit; only the ICS component is implicated in the pneumonia signal.
Option C: Option C is incorrect because fluconazole and fluticasone propionate have a well-documented clinically significant pharmacokinetic interaction — fluconazole is a potent CYP3A4 inhibitor that markedly raises systemic fluticasone propionate levels, risking iatrogenic Cushing's syndrome — making prophylactic fluconazole contraindicated with fluticasone propionate.
Option E: Option E is incorrect because characterizing budesonide and fluticasone propionate as having equivalent pneumonia risk is not accurate; available data — including the TORCH trial and subsequent analyses — demonstrate a more consistent and stronger pneumonia signal with fluticasone propionate-containing combinations than with budesonide-containing combinations in COPD; agent choice does matter clinically, but in this patient with eosinophils below 100 cells per microliter, ICS withdrawal rather than agent switching is the more appropriate action.

10. A 36-year-old woman with moderate persistent asthma has been on medium-dose budesonide/formoterol 160/4.5 mcg two inhalations twice daily for five months. She reports excellent control: no nocturnal awakenings, no SABA use in the past four months, no exacerbations, and an Asthma Control Questionnaire score of 24 (well-controlled threshold is 20 or above). She has no identified unresolved triggers. Her peak flow is stable at 96% predicted. She asks whether her medications can be reduced. Which of the following represents the most appropriate next step in managing her therapy?

A) Maintain her current regimen unchanged for a minimum of 12 months of sustained well-controlled asthma before any step-down is considered, because GINA guidelines require 12 consecutive months of documented well-controlled asthma — not 3 months — before step-down is appropriate, and initiating step-down after only 5 months risks premature loss of control
B) Discontinue the formoterol component and continue budesonide at the current medium dose as ICS monotherapy, because the LABA should always be removed before the ICS dose is reduced in any step-down from ICS/LABA combination therapy; retaining the full ICS dose while removing the LABA provides maximum anti-inflammatory protection during the step-down transition
C) Reduce the budesonide dose while maintaining formoterol, stepping from medium-dose to low-dose budesonide/formoterol combination, because she has met the 3-month minimum stability criterion for step-down consideration; the ICS dose is reduced first while the LABA is maintained to preserve bronchodilator protection during the dose reduction period
D) Discontinue both budesonide and formoterol simultaneously and switch to as-needed SABA only for a 4-week observation period, because her sustained control for 5 months indicates she may have achieved spontaneous remission; the observation period will determine whether she requires any ongoing controller therapy at all before committing to a stepped-down regimen
E) Add montelukast (an LTRA, leukotriene receptor antagonist) to her current medium-dose ICS/LABA regimen as the first step, then reduce the budesonide/formoterol dose in the second step; triple controller therapy must be established before any dose reduction to ensure sufficient pharmacological redundancy during the step-down transition

ANSWER: C

Rationale:

This patient has met the GINA prerequisite for step-down consideration — at least three months of sustained well-controlled asthma (she has had four months of no SABA use, no nocturnal symptoms, no exacerbations, and an Asthma Control Questionnaire score confirming well-controlled status). The correct step-down sequence from medium-dose ICS/LABA is to reduce the ICS dose by approximately 25 to 50% — moving from medium-dose budesonide/formoterol to low-dose budesonide/formoterol — while maintaining the formoterol component. Preserving the LABA during ICS dose reduction provides bronchodilator protection during the period when the reduced ICS dose may be insufficient to fully suppress airway inflammation; this pharmacological safety buffer reduces the risk of loss of control during the transition. Complete ICS withdrawal should not be attempted at this stage — it is deferred until the patient has achieved stability at step 2 (low-dose ICS monotherapy) or below for six months or more. Her five months of good control confirm the three-month minimum prerequisite is met, making the step-down appropriate at this visit.

Option A: Option A is incorrect because GINA guidelines specify a minimum of three months of sustained well-controlled asthma before step-down consideration, not 12 months; this patient has exceeded the minimum criterion and step-down is appropriate.
Option B: Option B is incorrect because removing the LABA before reducing the ICS dose reverses the guideline-recommended sequence; GINA specifies that when stepping down from ICS/LABA, the ICS dose should be reduced first while the LABA is maintained, not the reverse; removing LABA first eliminates bronchodilator protection during the most vulnerable period of the transition.
Option D: Option D is incorrect because abruptly discontinuing both ICS and LABA simultaneously in a patient with moderate persistent asthma is clinically inappropriate and poses high risk of acute loss of asthma control; stepwise reduction through established tiers is the correct approach, not binary discontinuation followed by observation.
Option E: Option E is incorrect because adding a third controller agent (montelukast) before reducing the existing combination represents step-up rather than step-down; there is no pharmacological rationale for adding LTRA to create "redundancy" before dose reduction, and this approach moves in the wrong therapeutic direction for a well-controlled patient.

11. A 55-year-old man with moderate persistent asthma is on medium-dose fluticasone propionate 250 mcg twice daily via pMDI (pressurized metered-dose inhaler) without a spacer. He reports a one-week history of soreness in his mouth and difficulty swallowing. Oral examination reveals creamy white patches on his buccal mucosa and soft palate that wipe off to reveal an erythematous base, consistent with oropharyngeal candidiasis. He has not used a spacer and does not routinely rinse his mouth after inhaler use. His asthma is currently well-controlled. Which of the following represents the most appropriate management?

A) Reduce fluticasone propionate to low-dose 100 mcg twice daily immediately to reduce oropharyngeal immunosuppression, and prescribe nystatin oral suspension 500,000 units four times daily for 14 days to treat the current infection; do not add a spacer because the dose reduction will reduce oropharyngeal deposition sufficiently to prevent recurrence without device modification
B) Prescribe topical antifungal therapy (nystatin oral suspension swish-and-swallow or clotrimazole troches) to treat the established candidiasis, add a valved holding chamber (spacer) to reduce future oropharyngeal drug deposition, and instruct the patient to rinse his mouth with water and spit after every inhalation; maintain the current fluticasone propionate dose because the infection is a preventable complication of inadequate technique rather than a dose-dependent adverse effect requiring ICS reduction
C) Switch from fluticasone propionate to ciclesonide at an equivalent anti-inflammatory dose without treating the current candidal infection, because ciclesonide's prodrug mechanism will prevent future oropharyngeal infections by eliminating local glucocorticoid receptor activation in oropharyngeal mucosa; the current candidal infection will resolve spontaneously once oropharyngeal drug activation ceases after the switch
D) Prescribe systemic oral fluconazole 150 mg as a single dose and add a spacer, but also switch from fluticasone propionate to budesonide because budesonide has lower GR (glucocorticoid receptor) binding affinity than fluticasone propionate and will produce less local oropharyngeal immunosuppression at equivalent microgram doses; lower GR affinity is the key determinant of oropharyngeal candidiasis risk when comparing ICS agents
E) Admit the patient for intravenous fluconazole because oropharyngeal candidiasis in a patient on ICS indicates systemic immunosuppression consistent with HPA (hypothalamic-pituitary-adrenal) axis suppression; the candidal infection cannot be treated topically in a patient with ICS-induced immunosuppression because topical agents cannot penetrate immunocompromised oropharyngeal mucosa

ANSWER: B

Rationale:

This patient's oropharyngeal candidiasis is a preventable complication of suboptimal inhaler technique — no spacer and no post-inhalation rinsing — rather than a dose-dependent adverse effect requiring ICS dose reduction or agent substitution. The management hierarchy has two components. First, treat the established infection: nystatin oral suspension or clotrimazole troches are appropriate first-line topical antifungal agents for mild-to-moderate oropharyngeal candidiasis; both are effective and have favorable safety profiles without systemic drug interactions. Second, correct the predisposing technique deficiencies: adding a valved holding chamber (spacer) reduces oropharyngeal impaction by slowing aerosol velocity and trapping larger particles before inhalation; post-inhalation mouth rinsing with expectoration removes residual drug from oropharyngeal surfaces before mucosal absorption can occur. Together these two measures directly address the causal mechanism — excess local ICS concentration in oropharyngeal tissue — without requiring any change to the ICS dose or agent. The current dose is appropriate for the patient's moderate persistent asthma, and the infection is attributable to remediable technique errors.

Option A: Option A is incorrect because ICS dose reduction is not the appropriate first response to candidiasis caused by absent spacer use and absent mouth rinsing; correcting technique can prevent recurrence without sacrificing asthma control through dose reduction, and the dose reduction proposed may be insufficient to maintain adequate asthma control.
Option C: Option C is incorrect because the current candidal infection requires active antifungal treatment and will not resolve spontaneously after an agent switch; ciclesonide's prodrug mechanism reduces but does not eliminate oropharyngeal adverse effects, and treating the established infection is essential regardless of subsequent agent changes.
Option D: Option D is incorrect because fluconazole is a potent CYP3A4 inhibitor that markedly increases systemic fluticasone propionate concentrations and risks iatrogenic Cushing's syndrome; prescribing fluconazole with fluticasone propionate is contraindicated; furthermore, GR binding affinity is not the primary determinant distinguishing ICS agents for oropharyngeal candidiasis risk — local drug deposition concentration is the primary driver.
Option E: Option E is incorrect because oropharyngeal candidiasis in a patient on inhaled ICS does not indicate systemic immunosuppression or HPA axis suppression; it represents local mucosal immunosuppression from topical drug deposition, not systemic glucocorticoid-mediated immune deficiency; the infection does not require hospitalization or intravenous antifungals, and topical agents are highly effective for oropharyngeal candidiasis in this context.